Physician profile
Hannah Park
NPI 1548657430
$5,527.56
in general payments reported to CMS, 2019-2025
21 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $180 · 2021: $428 · 2022: $865 · 2023: $1,234 · 2024: $1,394 · 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,890 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,890.37 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $728.12 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $557.08 | 2021-2025 | Idosetr, Idose |
| Sun Pharmaceutical Industries INC. | $503.12 | 2023-2025 | Cequa |
| Abbvie INC. | $453.69 | 2022-2025 | |
| Genentech USA, INC. | $408.34 | 2023-2025 | Vabysmo, Susvimo |
| Bausch & Lomb Americas INC. | $397.58 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Alcon Vision LLC | $347.58 | 2021-2025 | Hydrus Microstent, Tryptyr, Rhopressa |
| Johnson & Johnson Surgical Vision, INC. | $326.23 | 2020-2024 | Tecnis Iol |
| Biotissue Holdings INC. | $300.12 | 2020-2025 | |
| Harrow Eye, LLC | $237.09 | 2024-2025 | Vevye |
| Amgen INC. | $167.21 | 2024-2025 | Tepezza |
| Aerie Pharmaceuticals, INC. | $164.17 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $149.74 | 2022-2025 | Acthar |
| Carl Zeiss Meditec USA, INC. | $127.98 | 2022 | |
| Oyster Point Pharma, INC. | $122.60 | 2022-2025 | Tyrvaya |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $121.64 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $121.09 | 2020 | |
| Allergan, INC. | $114.03 | 2020-2022 | |
| Dompe US, INC. | $97.69 | 2022-2025 | Oxervate |
| Rxsight INC | $49.87 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Tarsus Pharmaceuticals, INC. | $32.59 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.